Sale of Orthobiologics Business (Tables)

9 Months Ended

Sep. 30, 2024

Sale of Orthobiologics Business

Schedules of assets and liabilities, financial results and cash flow reconciliation of the discontinued operations

The following table shows the financial results of the discontinued operations for the three and nine months ended September 30, 2023.

		Three Months Ended		Nine Months Ended
		September 30,		September 30,
	2023		2023
Net sales	$	2,291	$	12,894
Cost of goods sold		1,839		11,218
Gross profit		452		1,676
Sales and marketing		374		1,636
General and administrative		927		1,231
Research and development		262		776
Total operating expenses		1,563		3,643
Interest expense		117		348
Net income	$	(1,228)	$	(2,315)

Total operating and investing cash flows of discontinued operations for the nine months ended September 30, 2023 are comprised of the following:

		Nine Months Ended
		September 30,
	2023
Significant operating non-cash reconciliation items
Depreciation	$	213
Stock-based compensation		115
Changes in operating assets and liabilities:
Accounts receivable		745
Inventory		1,757
Prepaid expenses and other		(326)
Accounts payable and accrued expenses and other current liabilities		(920)
Obligations to tissue suppliers		(857)
Significant investing items
Expenditures for property, plant and equipment		287